Jpmorgan Chase & CO Immunovant, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Immunovant, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 256,843 shares of IMVT stock, worth $7.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

256,843

Previous 245,033 4.82%

Holding current value

$7.07 Million

Previous $7.92 Million 14.36%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$25.1 - $31.61 $296,431 - $373,314	11,810 Added 4.82%	256,843 $6.78 Million
Q1 2024 May 10, 2024	SELL	$30.27 - $43.79 $6.84 Million - $9.89 Million	-225,957 Reduced 47.97%	245,033 $7.92 Million
Q4 2023 Feb 12, 2024	BUY	$31.31 - $44.19 $1.33 Million - $1.88 Million	42,482 Added 9.91%	470,990 $19.8 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $259,718 - $559,479	-14,001 Reduced 3.16%	428,508 $16.5 Million
Q2 2023 Aug 11, 2023	BUY	$14.2 - $23.75 $5.4 Million - $9.04 Million	380,517 Added 613.82%	442,509 $8.39 Million
Q1 2023 May 18, 2023	BUY	$15.27 - $19.72 $938,830 - $1.21 Million	61,482 Added 12055.29%	61,992 $961,000
Q1 2023 May 11, 2023	SELL	$15.27 - $19.72 $762,034 - $984,106	-49,904 Reduced 98.99%	510 $7,000
Q4 2022 Feb 13, 2023	SELL	$6.59 - $17.75 $743,312 - $2 Million	-112,794 Reduced 69.11%	50,414 $895,000
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $1.93 Million - $3.12 Million	-489,973 Reduced 75.01%	163,208 $911,000
Q2 2022 Aug 11, 2022	BUY	$3.38 - $5.65 $647,604 - $1.08 Million	191,599 Added 41.51%	653,181 $2.55 Million
Q1 2022 May 11, 2022	BUY	$5.06 - $8.77 $1.57 Million - $2.72 Million	310,520 Added 205.56%	461,582 $2.54 Million
Q4 2021 Feb 10, 2022	SELL	$7.33 - $9.32 $1.52 Million - $1.94 Million	-207,731 Reduced 57.9%	151,062 $1.29 Million
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $2.52 Million - $4.08 Million	358,793 New	358,793 $3.12 Million

Others Institutions Holding IMVT

# of Institutions

215

Shares Held

65.3M

Call Options Held

697K

Put Options Held

629K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Immunovant, Inc. Transaction History